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Idiopathic hypercalciuria is the most common metabolic
abnormality in patients with nephrolithiasis. Through
successive inbreeding, we have developed a strain of rats
whose urine calcium (UCa) excretion is B8–10-fold greater
than that of control rats and who spontaneously form kidney
stones. We have termed these rats genetic hypercalciuric
stone-forming (GHS) rats. The physiology of the
hypercalciuria in the GHS rats closely parallels that of man.
We have recently shown that the GHS rat kidneys have an
increased number of receptors for calcium (CaR) compared to
Sprague–Dawley rats, the strain of rats originally bred to
develop the GHS rats. Calcimimetics, such as cinacalcet (Cin),
increase the sensitivity of the CaR to Ca. The effects of Cin on
UCa are complex and difficult to predict. We tested the
hypothesis that Cin would alter urinary (U) Ca and
supersaturation with respect to calcium hydrogen phosphate
(CaHPO4) and calcium oxalate (CaOx). GHS or control rats
were fed a normal Ca diet (0.6% Ca) for 28 days with Cin
(30 mg/kg/24 h) added to the diet of half of each group for
the last 14 days. The protocol was then repeated while the
rats were fed a low Ca (0.02% Ca) diet. We found that Cin led
to a marked reduction in circulating parathyroid hormone
and a modest reduction in serum Ca. Cin did not alter UCa
when the GHS rats were fed the normal Ca diet but lowered
UCa when they were fed the low Ca diet. However, Cin did
not alter U supersaturation with respect to either CaOx or
CaHPO4 on either diet. If these findings in GHS rats can be
confirmed in man, it suggests that Cin would not be an
effective agent in the treatment of human idiopathic
hypercalciuria and resultant stone formation.
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Hypercalciuria is the most common metabolic abnormality
found in humans with nephrolithiasis.1–5 Hypercalciuria
raises urine saturation with respect to the solid phases of
calcium hydrogen phosphate (CaHPO4, brushite) and calci-
um oxalate (CaOx), enhancing the probability of nucleation
and growth of crystals into clinically significant kidney
stones.1,2,4
We have established a model of hypercalciuria and
nephrolithiasis by successively inbreeding 67 generations of
the most hypercalciuric progeny of the most hypercalciuric
Sprague–Dawley rats found on an initial screen. Each rat now
excretes 8–10 times as much urinary calcium (UCa) as
similarly fed controls.6–23 The hypercalciuria is due to
increased intestinal Ca absorption6,7 coupled to a defect in
renal tubular Ca reabsorption7,14 and enhanced bone mineral
resorption,11 suggesting a systemic dysregulation of Ca
homeostasis.8 Human stone formers and these rats share
many metabolic features in common; many human stone
formers also have increased intestinal Ca absorption,
increased bone resorption, and decreased renal tubule Ca
reabsorption.1,3 Virtually all of these hypercalciuric rats form
kidney stones while there was no evidence of stone formation
in controls.10 We have termed the rats genetic hypercalciuric
stone-forming (GHS) rats.10,12,13,15,17–20 The stones formed
by the GHS rats fed standard rat chow contain only Ca and
phosphorus (P).10,13,18,19 The dietary addition of hydroxy-
proline, a common amino acid and an oxalate precursor,24
results in the formation of CaOx kidney stones.17,20
The Ca receptor (CaR) is a seven membrane-spanning
protein that is part of the G-coupled protein family of plasma
membrane receptors.25 The CaR is expressed in a wide variety
of tissues including parathyroids, kidney, and gastrointestinal
tract.26–28 There is marked homology between the parathyr-
oid and kidney CaR in a variety of animals including man
and rat.25,28 In the thick ascending limb of the loop of Henle,
the secretion of potassium into the lumen, through the
potassium channel ROMK, increases the lumen positive
voltage and drives Ca reabsorption through the paracellular
space.26 At this tubular site, elevation of the blood Ca level is
detected by the CaR, located on the plasma (anti-luminal)
membrane, decreasing potassium traffic through this channel
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resulting in decreased luminal positivity, decreased Ca
reabsorption, increased UCa, and a reduction in the
concentration of serum Ca.
The GHS rats have been found to have elevated levels of
vitamin D receptors (VDRs) in the intestinal mucosa, bone,
and renal cortex.8,11,16,23 Analogously, human stone formers
have also been shown to have an elevated number of VDRs in
their circulating monocytes.29 CaR contains vitamin D
response elements in its promoter region.30 We found that
there was increased CaR mRNA and protein in the GHS rat
kidney and that 1,25(OH)2D3 increased CaR levels through
both elevated CaR gene expression and prolonged tissue
half-life.21
The calcimimetics, such as cinacalcet (Cin), are small
organic molecules that act as allosteric activators of the CaR,
increasing the sensitivity of the CaR to serum Ca and sub-
stantially lowering parathyroid hormone (PTH) levels.31–33
In patients with secondary hyperparathyroidism treated
with Cin, there is a marked reduction of PTH (B50%)
and a modest reduction of serum Ca (B10%).31,33 The effect
of Cin on human UCa and supersaturations with respect to
common solid phases responsible for kidney stones has not
been reported.
The effects of Cin on renal tubular Ca reabsorption and
resulting UCa are complex. A reduction in PTH should
increase UCa; in addition, increasing the sensitivity of the
renal CaR to Ca should lead to an increase in UCa. However,
the lowered filtered load of Ca from Cin-induced hypocalce-
mia should lower UCa. In this study, we utilized the GHS rats
to test the hypothesis that Cin would alter urine Ca excretion
and supersaturation with respect to CaHPO4 and CaOx.
RESULTS
Serum PTH, Ca, and P
At the conclusion of the experiment, when all rats were being
fed low Ca diet (LCD), the serum PTH was significantly
lower in the GHS rats compared to the control (Ctl) rats
(Figure 1, top). The addition of Cin led to a significant fall in
PTH both in the Ctl and in the GHS rats compared to
respective non-Cin-fed rats. There was no difference in serum
PTH between the two Cin-fed groups. There was no
difference in serum Ca between the GHS and the Ctl rats
not fed Cin; however, the addition of Cin led to a significant
reduction in Ca both in the Ctl and in the GHS rats (Figure 1,
middle). There was no difference in serum Ca between the
two Cin-fed groups. Compared to the Ctl rats, serum P was
significantly lower in the GHS rats; the addition of Cin led to
an increase in serum P both in the Ctl and in the GHS rats
(Figure 1, bottom). Serum P was lower in the GHS rats fed
Cin compared to the Ctl rats fed Cin.
Urine Ca excretion
While being fed the normal Ca diet (NCD, 0.6% Ca), the
GHS rats excreted significantly more UCa compared to the
Ctl rats (Figure 2, top). With the addition of Cin to half of
each group, UCa remained significantly elevated in the GHS
rats compared to the Ctl rats whether or not they received
Cin. Cin did not alter UCa in either group. On the LCD
(0.02% Ca) without Cin, the GHS rats continued to excrete
significantly more UCa than the Ctl rats (Figure 2, bottom).
With the addition of Cin to the same rats that had received
Cin previously, UCa remained significantly elevated in the
GHS rats compared to the Ctl rats whether or not they
received Cin. Cin significantly lowered UCa in the GHS, but
not in the Ctl rats.
Urine P excretion
While being fed NCD the GHS rats excreted slightly, but
significantly, more P compared to the Ctl rats (Figure 3, top).
With the addition of Cin to half of each group, urine
phosphorus (UP) remained significantly greater in the GHS
rats compared to the Ctl rats whether or not they received
Cin. Cin did not alter UP in the Ctl or in the GHS rats. On
the LCD without Cin, the GHS rats continued to excrete
significantly more UP than the Ctl rats and there was a
significant increase in the P excretion for both Ctl and GHS
rats compared to NCD (Figure 3, bottom). With the addition
of Cin, UP was not different between the GHS and the Ctl
rats. Cin did not alter UP in the Ctl or in the GHS rats.
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Figure 1 | Serum PTH, Ca, and P at the conclusion of the
experiment. Fourteen 67th generation female GHS and 14 Ctl rats
were placed in metabolic cages. From days 1–14, each rat in each
group was fed NCD. From days 15 to 28, half of each group (seven
GHS and seven Ctl rats) was continued on NCD and the other half
(seven GHS and seven Ctl rats) were fed NCD supplemented with Cin.
From days 29 to 42, all GHS and Ctl rats were fed LCD. No rat received
Cin. From days 43 to 56, half of each group was continued on LCD
without modification and the other half (the same rats that had
previously received Cin) was fed LCD supplemented with Cin. Blood
was then drawn at the conclusion of day 56. Abbreviations: Ctl,
Sprague–Dawley rats; GHS, genetic hypercalciuric stone-forming rats;
NCD, 0.6% Ca and 0.65% P; LCD, 0.02% Ca and 0.65% P; Cin,
cinacalcet; *, Po0.05 vs Ctl; þ Po0.05 vs GHS; o, Po0.05 vs CtlþCin.
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Urine oxalate excretion
While being fed the NCD, the GHS rats excreted significantly
less oxalate (Ox) compared to the Ctl rats (Figure 4, top).
With the addition of Cin to half of each group, urine oxalate
(UOx) remained significantly lower in the GHS rats
compared to the Ctl rats whether or not they received Cin.
Cin led to a significant increase in UOx in the Ctl, but not the
GHS, rats. On the LCD without Cin, the GHS rats continued
to excrete significantly less UOx than the Ctl rats (Figure 4,
bottom). With the addition of Cin, UOx remained
significantly lower in the GHS rats compared to the Ctl
rats. Cin significantly increased UOx in the Ctl and in the
GHS rats.
Urine CaHPO4 supersaturation
While being fed NCD, the GHS rats had a significantly higher
urinary supersaturation (USS) for CaHPO4 (brushite)
compared to the Ctl rats (Figure 5, top). With the addition
of Cin, USS for CaHPO4 remained significantly elevated in
the GHS rats compared to the Ctl rats whether or not they
received Cin and Cin did not alter USS for CaHPO4 in either
group. On the LCD without Cin, the GHS rats continued to
have a significantly higher USS for CaHPO4 than the Ctl rats
(Figure 5, bottom). With the addition of Cin, USS for
CaHPO4 remained significantly elevated in the GHS rats
compared to the Ctl rats whether or not they received Cin.
Cin did not alter USS for CaHPO4 in the GHS or in the
Ctl rats.
Urine CaOx supersaturation
While being fed NCD, the GHS rats had a significantly higher
USS for CaOx compared to the Ctl rats (Figure 6, top). With
the addition of Cin, USS for CaOx remained significantly
elevated in the GHS rats compared to the Ctl rats whether or
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Figure 2 | Urine Ca excretion at the four different urine collection
periods. Fourteen 67th generation female GHS and 14 Ctl rats were
placed in metabolic cages. From days 1 to 14, each rat in each group
was fed NCD. During the last 5 days of this period (days 10–14), five
successive 24-h urine collections were obtained. From days 15 to 28,
half of each group was continued on NCD and the other half were fed
NCD supplemented with Cin. During the last 5 days of this period
(days 24–28), five successive 24-h urine collections were obtained.
From days 29 to 42, all GHS and Ctl rats were fed LCD. No rat received
Cin. During the last 5 days of this period (days 38–42), five successive
24-h urine collections were obtained. From days 43 to 56, half of each
group was continued on LCD without modification and the other half
(that had previously received Cin) was fed LCD supplemented with
Cin. During the last 5 days of this period (days 52–56), five successive
24-h urine collections were obtained. Abbreviations: Ctl, Sprague–-
Dawley rats; GHS, genetic hypercalciuric stone-forming rats; NCD,
0.6% Ca and 0.65% P; LCD, 0.02% Ca and 0.65% P; Cin, cinacalcet;
*Po0.05 vs Ctl, same time period; þ Po0.05 vs GHS, same time
period; o, Po0.05 vs CtlþCin, same time period.
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Figure 3 | Urine P excretion at the four different collection
periods. Protocol and abbreviations as in Figure 2.
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Figure 4 | Urine Ox excretion at the four different collection
periods. Protocol and abbreviations as in Figure 2.
1588 Kidney International (2006) 69, 1586–1592
o r i g i n a l a r t i c l e DA Bushinsky et al.: Effect of cinacalcet on urine calcium excretion
not they received Cin and Cin did not alter USS for CaOx in
either group. On the LCD without Cin, the GHS rats
continued to have a significantly higher USS for CaOx than
the Ctl rats (Figure 6, bottom). With the addition of Cin, USS
for CaOx remained significantly elevated in the GHS rats
compared to the Ctl rats whether or not they received Cin.
Cin did not alter USS for CaOx in the GHS or in the Ctl rats.
Urine volume, creatinine clearance, and filtered load of Ca
The GHS rats were polyuric (3271.7 ml/24 h) compared to
the Ctl rats (21.972.4, Po0.05) on NCD and on LCD
(19.470.9 ml/24 h GHS vs 14.670.9 Ctl, Po0.05) and Cin
did not alter urine volume. There was no difference in the
creatinine clearance between the GHS (0.9570.05 ml/min)
and Ctl (1.0970.05) rats on LCD and Cin did not alter the
creatinine clearance (0.9670.03 ml/min, GHS7Cin vs
1.0770.08 Ctl7Cin). There was no significant difference
in the filtered load of Ca between the GHS (72.973.0 mg Ca/
min) and Ctl (78.773) rats on LCD; however, Cin
significantly lowered the filtered load of Ca in both the
GHS (60.872.3) and the Ctl (57.271.4) rats compared to
similar rats not fed Cin (both Po0.05).
DISCUSSION
The GHS rats were bred for hypercalciuria, the most common
metabolic abnormality in patients with nephrolithiasis.
Studies of the pathophysiology of the hypercalciuria in the
GHS rats reveal that, similar to many patients with idiopathic
hypercalciuria, they have increased intestinal Ca absorption,6,7
reduced renal Ca reabsorption,7,14 and excessive bone
demineralization.11 The dysregulation of Ca transport at these
sites suggests a systemic abnormality in Ca homeostasis.8
Indeed, we have shown that there is an increase in the number
of VDR in intestine, bone, and kidney8,11,16,23 and CaR in
kidney21 of the GHS compared to non-hypercalciuric
Sprague–Dawley rats, the parental strain of the GHS rats.
Where there is a reduction in renal tubular Ca reabsorp-
tion, the overriding mechanism for promoting hypercalciuria
in the GHS rat, we would expect to observe a fall in serum Ca
leading to an increase in PTH.34 Indeed, kidney stone
patients with so-called ‘renal hypercalciuria’ have elevated
levels of PTH.1,2 On LCD, the serum level of PTH in the GHS
rat was lower than that in Ctl rats, suggesting that even on
this reduced level of dietary Ca, the hypercalciuria in the GHS
rat was driven more by enhanced intestinal Ca absorption
and/or bone demineralization than by a reduction in renal
tubular Ca reabsorption. Serum Ca was not different between
the GHS and Ctl rats and serum P was slightly, but
significantly, lower in the GHS compared to the Ctl rats.
The reason for this decrease in serum P is not apparent but is
consistent with a decrease in serum P found in descriptions
of some hypercalciuric patients.1,2
The relationship of serum Ca to PTH secretion seems to
be shifted to the right in the GHS rats compared to Ctl, since
lower levels of serum PTH are required to maintain similar
levels of serum Ca. This may be due to a higher density of
CaR in the parathyroid glands of the GHS rat, leading to an
amplification of the serum Ca signal. The higher density of
CaR in the kidneys of GHS rat could also play a role in the
lower tubular Ca reabsorption found in the GHS rat. The
lower serum PTH levels in the GHS rat compared to Ctl
might also be explained by the potential for higher
parathyroid gland VDR levels in the GHS rats.8,11,16,23 Since
calcitriol suppresses PTH secretion, elevated VDR in the
parathyroid glands would accentuate calcitriol action. The
factors that are most important in determining the relation-
ship between serum Ca and PTH in the GHS rat are not clear
at this time.
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Figure 5 | Urine supersaturation with respect to the CaHPO4
(brushite) solid phase at the four different collection periods.
Protocol and abbreviations as in Figure 2.
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Figure 6 | Urine supersaturation with respect to the CaOx solid
phase at the four different collection periods. Protocol and
abbreviations as in Figure 2.
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Recently, small molecules that increase the sensitivity of
the CaR to Ca, the calcimimetics, have been developed for the
treatment of human primary and secondary hyperparathyr-
oidism.31–33 The calcimimetic approved for use in man, Cin,
has been shown to markedly reduce serum PTH levels and
modestly reduce levels of serum Ca.31,33 Because of the effects
of both the filtered load of Ca and the level of PTH to alter
renal tubular Ca reabsorption, the effects of a calcimimetic
on UCa are difficult to predict. However, if Cin were to reduce
UCa and supersaturation with respect to a crystal solid phase
such as CaOx and/or CaHPO4, it might be useful in the
pharmacological therapy of hypercalciuric stone formers. We
found that although Cin reduced serum PTH and Ca in the
GHS and control rats, it did not alter urine supersaturation
with respect to CaOx or CaHPO4 in either strain.
Cin increases the sensitivity of the CaR to Ca, thereby
shifting the sigmoidal-shaped relationship between Ca and
PTH to the left, resulting in a reduction of PTH secretion and
serum levels.31–33 Cin led to a marked reduction in PTH and
serum Ca in both the GHS and Ctl rats. This is consistent
with findings in humans treated with this calcimimetic.31–33
As PTH is phosphaturic, the reduced PTH should lead to an
increase in serum P as shown in this study.34
Urine Ca in the GHS rats far exceeded that in the Ctl rats
on both NCD and LCD. On LCD, UCa in the GHS rats
exceeded that of available dietary Ca, indicating that bone
must have contributed to the excessive UCa in the GHS rats.
This is consistent with our previous observations that the
GHS rats are in negative Ca balance on LCD7 and
alendronate, a bisphosphonate which inhibits bone resorp-
tion, markedly reduced UCa in GHS rats fed LCD.15 That
UCa fell with Cin in the GHS rats fed LCD suggests that PTH
is necessary to resorb the bone mineral that contributes to the
hypercalciuria of the GHS rats fed LCD. UCa was not
appreciably different in the Ctl rats fed NCD compared to
LCD, indicating that in Ctl rats even on LCD there is
adequate dietary Ca to maintain urinary Ca excretion. That
the Ctl rats fed Cin did not lower their UCa on NCD or LCD,
in spite of a decreased filtered load of Ca, suggests that Cin
also may have affected the renal CaR, resulting in a decreased
renal tubular Ca reabsorption.
The effect of Cin on UCa is difficult to predict. PTH
induces the renal tubule to increase Ca reabsorption from the
glomerular filtrate indicating that a reduction in PTH
induced by Cin should increase UCa.34 A fall in serum Ca
induced by Cin should reduce the filtered load of Ca and lead
to a decrease in UCa.34 However, if Cin influences the renal
CaR, increasing its sensitivity to Ca may lead to an increase in
UCa. Cin did not alter UCa excretion in either the GHS or
Ctl rats fed NCD and lowered UCa in the GHS rats fed LCD
but not in the Ctl rats fed LCD. Further studies, perhaps
using parathyroidectomized GHS and Ctl rats perfused with
a constant amount of Ca as we have previously done with
GHS rats not given Cin,14 will be necessary to understand
the multiple interactions between PTH, Cin, and the filtered
load of Ca.
Urine P was higher in the GHS rats than in the Ctl rats on
both the NCD and LCD and, as noted above, serum P was
lower in the GHS rats despite a reduced level of the
phosphaturic hormone PTH. Whether other phosphaturic
compounds are increased in the GHS rat is not known at this
time. UP excretion increased substantially in both groups of
rats when they were changed from NCD to LCD. Dietary Ca
binds intestinal P, reducing P absorption,35 so that a
reduction in dietary Ca would be expected to result in an
increase in UP. LCD will also increase calcitriol production,
which will increase intestinal P absorption. It is unclear why
UOx in the GHS rats was lower than that of Ctl rats when fed
either NCD or LCD and why the addition of Cin led to an
increase in UOx in the Ctl rats fed NCD and in the Ctl and
GHS rats fed LCD.
In this study, we found that Cin did not alter super-
saturation with respect to either solid phase in either the
GHS or Ctl rats when fed the NCD or LCD. If these findings
in the GHS rats can be confirmed in man, it suggests that Cin
would not be an effective agent in the treatment of idiopathic
hypercalciuria in humans.
MATERIALS AND METHODS
Establishment of hypercalciuric rats
Adult Sprague–Dawley rats (Charles River Laboratories, Kingston,
NY, USA) were initially screened for hypercalciuria by placing the
rats in individual metabolic cages, feeding them a constant amount
of a standard Ca diet, and measuring urine Ca excretion. The most
hypercalciuric male and female rats were used to breed the next
generation. A similar protocol was used for screening and
inbreeding of subsequent generations.6,8,10,16,17,20–23
Study protocol
Fourteen 67th generation female GHS rats and 14 female
Sprague–Dawley Ctl rats, initially weighing on average 238 g, were
placed in metabolic cages. From days 1 to 14, each rat in each group
was fed 13 g/day of a NCD (0.6% Ca and 0.65% P, Harlan Teklad,
Madison, WI, USA). We have previously shown that rats of this size
completely consume this amount of diet on a daily basis.15,17–20
During the last 5 days of this period (day 10–14), five successive 24-h
urine collections were obtained. Three (first, second, fourth) were
collected in concentrated HCl (0.5 ml) for all measurements except
for pH, uric acid, and chloride and two collections (third and fifth)
were collected in the presence of thymol for measurement of pH,
uric acid, and chloride. All samples were refrigerated at 41C until
measurement and all measurements were completed within 2 weeks.
From days 15 to 28, half of each group (seven GHS and seven Ctl
rats), chosen at random, was continued on NCD without
modification and the other half (seven GHS and seven Ctl rats)
was fed NCD supplemented with Cin (30 mg/kg/day) (Amgen Inc.,
Thousand Oaks, CA, USA). This dose has been shown to
significantly inhibit PTH in normal rats.36 In humans, the terminal
half-life of Cin is 30–40 h and steady-state drug levels are reached in
7 days.36,37 During the last 5 days of this period (day 24–28),
five successive 24-h urine collections were obtained as during
days 10–14.
From days 29 to 42, all GHS and Ctl rats were fed 13 g/day of a
LCD (0.02% Ca and 0.65% P, Harlan Teklad, Madison, WI, USA).
No rat received Cin. LCD was utilized to remove the contribution of
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appreciable intestinal Ca absorption to UCa excretion. During the
last 5 days of this period (day 38–42), five successive 24-h urine
collections were obtained as during days 10–14.
From days 43 to 56, half of each group (seven GHS and seven Ctl
rats) was continued on LCD without modification and the other half
(the same seven GHS and seven Ctl rats that had previously received
Cin) was fed LCD supplemented with Cin (30 mg/kg/day). During
the last 5 days of this period (day 52–56), five successive 24-h urine
collections were obtained as during days 10–14.
Each rat had access to deionized distilled water ad libitum. Any
rat that ate less than 12 g of food per day or drank less than 15 ml of
water on any day would have been excluded from the study;
however, all rats met these prospective criteria throughout the study.
At the conclusion of the experiment, each rat received an
intraperitoneal injection of sodium pentobarbital (Nembutal) to
induce complete anesthesia. Blood was collected through the carotid
artery, in uncoated centrifuge tubes for determination of serum Ca,
P, and creatinine and in ethylenediaminetetraacetic acid-coated
tubes for determination of PTH. After centrifugation and separation
of serum, the samples were stored at 41C (Ca/P) or 701C (PTH)
until analysis. The kidneys were not examined for stones.
Urine chemical determinations
UCa, creatinine, inorganic P, uric acid, magnesium, ammonia,
sodium, potassium, chloride, oxalic acid, citric acid, pH, and sulfate
were measured using methods previously described.15,17–20,22 The
filtered load of Ca was calculated by multiplying the serum Ca times
the fraction of Ca that is ultrafiltrable times the creatinine clearance.
We have previously determined that the ultrafiltrable Ca in the GHS
rat is 0.725 times the total Ca.14
Urine supersaturation
The CaOx and the CaHPO4 ion activity products were calculated
using the computer program EQUIL developed by B Finlayson and
associates.38–40 The computer program calculates free ion concen-
trations using the concentrations of measured ligands and known
stability constants. Ion activity coefficients are calculated from ionic
strength using the Davies modification of the Debye–Huckel
solution to the Poisson–Boltzman equation. The program simulta-
neously solves for all known binding interactions among the
measured substances. Oxalate, P, and Ca ion activities were used to
calculate the free-ion activity products. The relative supersaturation
for CaOx is calculated as the ratio of the free-ion activity product of
Ca and Ox in the individual urine to the solubility of CaOx. The
relative supersaturation for CaHPO4 is calculated as the ratio of the
free-ion activity product of Ca and P in the individual urine to the
solubility of CaHPO4. Ratios of 1 connote a sample at equilibrium,
above 1 supersaturation, and below 1 undersaturation. We have used
this computer program previously and found excellent correspon-
dence between calculated and experimentally measured saturation
in urine and blood.7,9,10,12,13,15,17–20,22
Blood determinations
Serum Ca was measured by atomic absorption using a Perkin–Elmer
AA 100 (Perkin–Elmer Inc., Wellesley, MA, USA). Serum P and
creatinine were measured on a Beckman Synchron CX5CE
autoanalyzer (Beckman Instruments, Brea, CA, USA) by the
phosphomolybdate method and the alkaline picrate method,
respectively. Serum PTH was determined using a rat bioactive
intact PTH enzyme-linked immunosorbent assay (Immutopics, Inc.,
San Clemente, CA, USA).
Statistical analyses
All values are expressed as mean7s.e.m. Tests of significance were
calculated by t tests and analysis of variance, as appropriate, using
conventional computer programs (BMDP, University of California,
Los Angeles, CA, USA). Po0.05 was considered significant.
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